$1.14bn For Xtandi Royalties: How UCLA Cut Risk, Diversified Its Assets
This article was originally published in Scrip
Executive Summary
With no shortage of offers to buy its royalties from the prostate cancer drug Xtandi (enzalutamide), the University of California, Los Angeles (UCLA) recently decided to reduce its risk and diversify its holdings by selling the Xtandi revenue stream, accepting a bid from Royalty Pharma for $1.14bn.